Current and future developments in screening for ovarian cancer

Women's Health

Volumn 2, Issue 5, 2006, Pages 733-742

  Urban, Nicole ^a   Drescher, Charles ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

Biomarkers; Ovarian cancer; Prophylactic surgery; Risk; Screening

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; EOSINOPHIL PROTEIN X; KALLIKREIN; LEPTIN; MESOTHELIN; ONCOPROTEIN; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B;

ABDOMINAL SURGERY; ANTIGEN DETECTION; BLOOD SAMPLING; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; MEDICAL RESEARCH; OVARIECTOMY; OVARY CANCER; OVARY DISEASE; PAPANICOLAOU TEST; PATIENT SELECTION; PREGNANCY; PROTEOMICS; REVIEW; SALPINGOOOPHORECTOMY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYMPTOM; TRANSVAGINAL ECHOGRAPHY; UNNECESSARY PROCEDURE;

EID: 33749515465     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.5.733     Document Type: Review

References (52)

1. Urban N, McIntosh MW, Clarke L et al.: Socio-economics of ovarian cancer screening. In: Ovarian Cancer 6. Jacobs IJ, shepherd JH, Oram DH et al., (Eds), Oxford University Press, New York, USA 199-208 (2002).
2. Etzioni R, Urban N, Ramsey S et al.: The case for early detection. Nat. Rev. Cancer 3(4), 243-252 (2003).
3. Dove-Edwin I. Sasieni P, Adams J, Thomas HJW: Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 331 (7524), 1047 (2005).
4. Sanders ME, Schuyler PA, Dupont WD, Page DL: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12), 2481-2484 (2005).
5. Powell CB, Kenley E, Chen LM et al.: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23(1), 127-132 (2005).
6. Prat J, Ribe A, Gallardo A: Hereditary ovarian cancer. Hum. Pathol. 36(8), 861-870 (2005).
7. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol. Oncol. 98(2), 179-181 (2005).
8. Rosen B, Kwon J, Fung Kee Fung M. Gagliardi A, Chambers A: Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol. Oncol. 93(2), 280-286 (2004).
9. Finch A, Shaw P, Rosen B et al: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 100(1), 58-64 (2006).
10. Leeper K, Garcia R, Swisher E et al.: Pathologic Findings in Prophylactic Oophorectomy Specimens in High-Risk Women. Gynecol. Oncol. 87 (1), 52-56 (2002).
11. Eisen A, Lubinski J, Klijn J et al.: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case control study. J. Clin. Oncol. 23(30). 7491-7496 (2005).
12. Rebbeck TR, Lynch HT, Neuhausen SL et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Eng. J. Med. 346(21), 1616-1622 (2002).
13. King MC, Marks JH, Mandell JB, for the New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
14. Buys SS, Partridge E, Greene MH et al.: Ovarian cancer screening in the Prostate, Lung. Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193(5), 1630-1639 (2005).
15. DePriest PD, DeSimone CP: Ultrasound Screening for the Early Detection of Ovarian Cancer. J.Clin. Oncol. 21(Suppl. 10), 194-199 (2003).
16. van Nagell JR, Jr., DePriest PD, Reedy MB et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77(3), 350-356 (2000).
17. Fishman DA, Cohen L, Blank SV et al.: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am. J. Obstet. Gynecol. 192(4), 1214-1221 (2005).
18. van Haaften-Day C, Shen Y, Xu F et al.: OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer 92(11), 2837-2844 (2001).
19. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol. Oncol. 100(1), 20-26 (2006).
20. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J. Clin. Oncol. 22(7), 1315-1327 (2004).
21. Stirling D, Evans DG, Pichert G et al.: Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System. J. Clin. Oncol. 23(24), 5588-5596 (2005).
22. Skates SJ, Menon U, MacDonald N et al.: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21(10), S206-S210 (2003).
23. Menon U, Skates SJ, Lewis S et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23(31), 7919-7926 (2005).
24. Jacobs IJ, Skates SJ. MacDonald N et al.: Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353(9160), 1207-1210 (1999).
25. Kramer BS, Gohagan J, Prorok PC, Smart C: A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71(Suppl. 2), 589-593 (1993).
26. Terry KL, Sluss PM, Skates SJ et al.: Blood and urine markers for ovarian cancer: a comprehensive review. Dis. Markers 2053-2070 (2004).
27. Petricoin III EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
28. Rapkiewicz AV, Espina V, Petricoin I, Emanuel F, Liotta LA: Biomarkers of ovarian tumours. Eur. J. Cancer 40(17). 2604-2612 (2004).
29. Ye B, Skates S, Mok SC et al.: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12(2), 432-441 (2006).
30. Mor G, Visintin I, Lai Y et al.: Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102(21), 7677-7682 (2005).
31. Draghici S, Chatterjee M, Tainsky MA: Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev. Mol. Diagn. 5(5). 735-743 (2005).
32. Skates SJ, Horick N, Yu Y et al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22(20), 4059-4066 (2004).
33. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695-3700 (2003).
34. Scholler N, Fu N, Yang Y et al.: Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl Acad. Sci. USA 96(20). 11531-1156 (1999).
35. Diamandis EP, Borgono CA, Scorilas A et al.: Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin. Biochem. 37(9), 823-829 (2004).
36. Salceda, S, Tang T, Kmet M et al.: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306(1), 128-141 (2005).
37. Bast RC Jr, Badgwell D, Lu Z et al.: New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15 (Suppl.), 3274-3281 (2005).
38. McIntosh MW, Drescher C, Karlan B et al.: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95(1), 9-15 (2004).
39. Scholler N, Crawford M, Sato A et al.: Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res. 12(7), 2117-2124 (2006).
40. Rosen DG, Wang L, Atkinson JN et al.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267-277 (2005).
41. McIntosh MW, Urban N: A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4(1), 27-40 (2003).
42. McIntosh MW, Urban N, Karlan B: Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol. Biomarkers Prev. 11(2), 159-166 (2002).
43. Bjorge T, Lie A, Hovig E et al.: BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br. J. Cancer. 91(10). 1829-1834 (2004).
44. Horluchi A, Itoh K, Shimizu M et al.: Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol. Oncol. 88(3), 309-317 (2003).
45. Kauff ND, Satagopan JM, Robson ME et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346(21), 1609-1615 (2002).
46. Schmeler KM, Lynch HT, Chen LM et al.: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 345(3), 261-269 (2006).
47. Casey MJ, Synder C, Bewtra C et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol. Oncol. 97(2). 457-467 (2005).
48. Madalinska JB, Hollenstein J, Bleiker E et al.: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol. 23(28), 6890-6898 (2005).
49. Robson M. Hensley M, Barakat R et al.: Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol. Oncol. 89(2), 281-287 (2003).
50. Rebbeck TR, Friebel T, Wagner T et al.: Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study Group. J Clin. Oncol. 23(31), 7804-7810 (2005).
51. Kerner R, Sabo E, Gershoni-Baruch R, Beck D, Ben-Izhak O: Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. Gynecol. Oncol. 99(2), 367-375 (2005).
52. Drapkin R, von Horsten HH, Lin Y et al.: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65(6), 2162-2169 (2005).